GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Zai Lab Limited
Zai Lab is a Chinese biopharmaceutical company that licenses and develops innovative drugs for the Chinese market. Its share price is dependent on clinical trial success, regulatory approvals in China, and partnerships with Western biotech companies.
Share prices of companies in the market segment - Pharma holding
Zai Lab is a Chinese biopharmaceutical company that licenses and develops innovative drugs for the Chinese market. We classify it as a Pharma Holding, and the chart below reflects the overall dynamics of this market segment.
Broad Market Index - GURU.Markets
Zai Lab is a Chinese biopharmaceutical company that licenses and develops innovative drugs for the Chinese and global markets. As a component of the GURU.Markets index, it bridges the gap between the Western and Eastern pharmaceutical industries. The chart below shows the US market. See how Zai Lab shares compare to the US market.
Change in the price of a company, segment, and market as a whole per day
ZLAB - Daily change in the company's share price Zai Lab Limited
Change_co for Zai Lab, a biopharmaceutical company, reflects the high volatility inherent in the sector. Daily price fluctuations demonstrate sensitivity to research results and partnerships. At System.GURU.Markets, this metric is key for building risk assessment models in the global biotech industry.
Daily change in the price of a set of shares in a market segment - Pharma holding
Zai Lab Limited is a Chinese biotech company. This chart highlights the sector's high volatility. Comparing it to ZLAB, whose model is based on licensing Western drugs for the Chinese market, helps assess its unique risk profile.
Daily change in the price of a broad market stock, index - GURU.Markets
Zai Lab is a Chinese biopharmaceutical company that licenses and develops drugs for the Chinese market. Chinese biotech stocks are known for their high volatility. The chart below shows average market fluctuations, which are also influenced by these international players.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Zai Lab Limited
Zai Lab is a Chinese biotechnology company that licenses and launches Western drugs in China. Its business model straddles the intersection of biotech and the specifics of the Chinese market. Its stock price reflects both scientific and geopolitical risks.
Annual dynamics of market capitalization of the market segment - Pharma holding
Zai Lab Limited is a Chinese biopharmaceutical company that licenses and develops innovative drugs for the Chinese market. Its unique "in-China-for-China" model is its key advantage. The chart shows how its successful partnerships and access to a vast market contribute to its rapid growth.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Zai Lab is a Chinese biotech company whose stock price (ADR) is driven by two factors: the success of its R&D platform and investor sentiment toward the Chinese market. The chart tells a complex story, where scientific potential battles geopolitical and regulatory risks.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Zai Lab Limited
The value of Zai Lab, a Chinese biopharmaceutical company, depends on its product cycle. Monthly fluctuations on the chart reflect successes in commercializing licensed drugs in China and progress in developing its own drugs, making the company sensitive to decisions by Chinese regulators.
Monthly dynamics of market capitalization of the market segment - Pharma holding
Zai Lab is a biopharmaceutical company focused on licensing and developing innovative drugs for the Chinese market. They are building a bridge between Western innovation and China's vast healthcare market. The chart below shows the overall dynamics of the global pharmaceutical sector, reflecting the growing role of Asian markets.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Shares of biotech companies targeting the Chinese market combine R&D risks with country risks. The chart below shows the dynamics of global markets. Is Zai Lab moving at its own pace, driven by both science and Chinese regulators?
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Zai Lab Limited
Zai Lab, a Chinese biopharmaceutical company that licenses and develops drugs for the global market, is influenced by both scientific and geopolitical factors. Its weekly stock price reflects news about clinical trials and regulatory relations between China and the US.
Weekly dynamics of market capitalization of the market segment - Pharma holding
Biopharmaceutical companies operating in the Chinese market, like Zai Lab, are exposed to common regulatory risks and the unique characteristics of the Chinese healthcare system. The chart below reflects these factors and compares the success of Zai Lab's business model for licensing Western drugs to China compared to that of local developers.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Zai Lab is a Chinese biopharmaceutical company that licenses and develops drugs for the Chinese market. Its dynamics are a mixture of biotech risks and geopolitics. The chart shows how the company's shares react to news from these two areas, often moving independently of global markets.
Market capitalization of the company, segment and market as a whole
ZLAB - Market capitalization of the company Zai Lab Limited
Zai Lab's market capitalization chart reflects investors' bets on its unique business model as a "bridge" between the Western and Chinese pharmaceutical markets. Its dynamics reflect its success in licensing and developing innovative drugs for China. The scale of this metric demonstrates its key role in providing access to cutting-edge medicines for millions of patients.
ZLAB - Share of the company's market capitalization Zai Lab Limited within the market segment - Pharma holding
Zai Lab is a biopharmaceutical company with a unique market position. It licenses promising Western drugs for development and commercialization in China, serving as a bridge between global innovation and the vast Chinese market.
Market capitalization of the market segment - Pharma holding
This graph shows the total market value of the entire pharmaceutical sector. For Zai Lab, a unique Chinese company that licenses and brings cutting-edge Western drugs to the Chinese market, this line represents an opportunity map. A rising graph in the West signifies the emergence of new promising drugs that Zai Lab can bring to the vast Chinese market.
Market capitalization of all companies included in a broad market index - GURU.Markets
Zai Lab is a Chinese biopharmaceutical company that brings innovative drugs to market. Its market capitalization relative to the global market is an indicator of China's growing role in the global healthcare industry. It represents the share of Asian innovation in global medicine.
Book value capitalization of the company, segment and market as a whole
ZLAB - Book value capitalization of the company Zai Lab Limited
Zai Lab is a biopharmaceutical company focused on bringing innovative drugs to the Chinese market. Its book value reflects its capital for drug licensing, as well as its own R&D centers and laboratories. This represents its financial and scientific bridge. How has this foundation for innovation grown? The chart below illustrates this dynamic.
ZLAB - Share of the company's book capitalization Zai Lab Limited within the market segment - Pharma holding
Zai Lab Limited is building a bridge between the Chinese and global pharmaceutical markets, and to this end, it is creating its own infrastructure. The company is investing in the construction of modern R&D centers and manufacturing facilities in China. The chart shows its growing share of physical assets necessary for the localization and development of advanced drugs.
Market segment balance sheet capitalization - Pharma holding
Zai Lab is a biopharmaceutical company focused on China. Pharmaceuticals, as the chart shows, are capital-intensive. Zai Lab uses a smart model: it licenses promising Western drugs and invests in R&D and commercial infrastructure to bring them to the Chinese market.
Book value of all companies included in the broad market index - GURU.Markets
Zai Lab is building a bridge between the Chinese and global pharmaceutical markets. The company's book value is derived from its state-of-the-art research and production centers in China and the United States. The chart shows the real, tangible capital behind its business model, which aims to accelerate access to innovative medicines in Asia.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Zai Lab Limited
Zai Lab owns laboratories, but its business model is a bridge between the West and China. The chart shows the premium the market pays for its unique expertise in conducting clinical trials and registering Western drugs in China. This is a valuation not of its assets, but of its strategic position.
Market to book capitalization ratio in a market segment - Pharma holding
Zai Lab is a Chinese biopharmaceutical company that licenses and develops innovative drugs for the Chinese market. Its model is based on partnerships and research. The chart shows how much investors believe in its ability to successfully introduce Western drugs to the vast Chinese market.
Market to book capitalization ratio for the market as a whole
Zai Lab is a Chinese biopharmaceutical company that licenses and develops innovative drugs for the Chinese and global markets. Its business model is to discover promising developments in the West and bring them to the Chinese market. This chart shows general valuations, but how do investors view a company that bridges global innovation and a massive market?
Debts of the company, segment and market as a whole
ZLAB - Company debts Zai Lab Limited
Zai Lab, a biopharmaceutical company focused on the Chinese market, builds its strategy on licensing and drug development. Debt capital can be used to acquire rights to promising new drugs, finance costly clinical trials, and launch products into the vast Chinese market.
Market segment debts - Pharma holding
Zai Lab Limited is a biopharmaceutical company focused on licensing and developing innovative drugs for the Chinese and global markets. This business model requires significant resources to acquire drug rights and conduct local trials. This chart shows how the company finances its development pipeline.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Zai Lab Limited
Zai Lab is a biopharmaceutical company focused on licensing and developing innovative drugs for the Chinese market. This chart shows how it finances its drug portfolio. For a company whose business is based on partnerships and clinical trials, managing capital and debt is key to developing multiple drugs simultaneously.
Market segment debt to market segment book capitalization - Pharma holding
Developing cancer drugs for the Asian market, Zai Lab's specialty, requires significant investments in clinical trials and licensing. This chart shows the overall debt burden in the biotech sector. It allows one to assess how Zai Lab's unique business model (licensing Western drugs) impacts its financial structure compared to the industry.
Debt to book value of all companies in the market
This chart shows the overall debt level for all companies in the market. Zai Lab, which licenses Western drugs to China, has a unique business model. A comparison with the overall market allows us to assess how its strategy, which is less risky than developing a complete product from scratch, impacts its debt policy compared to the average biotech company and the market.
P/E of the company, segment and market as a whole
P/E - Zai Lab Limited
This chart for Zai Lab, a biopharmaceutical company focused on the Chinese market, shows how investors view its strategy. The multiple reflects their belief in the company's ability to successfully license, develop, and commercialize innovative Western drugs for China's vast and growing healthcare market.
P/E of the market segment - Pharma holding
The biopharmaceutical industry in China, where Zai Lab licenses Western drugs, is a unique model. This chart shows the average valuation for biopharmaceutical companies. It helps to understand that Zai Lab is valued as a bridge to the vast Chinese market, and its value depends on the successful commercialization of the drugs it licenses.
P/E of the market as a whole
Zai Lab Limited is a biopharmaceutical company focused on developing and commercializing innovative drugs for the treatment of oncology, autoimmune, and infectious diseases in China and globally. This chart reflects overall investor interest in biotech. It helps us understand what influences ZLAB's valuation more: global biotech trends or its unique position in the rapidly growing Chinese market.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Zai Lab Limited
Zai Lab is a Chinese biopharmaceutical company that licenses and develops innovative drugs for the Chinese and global markets. This chart reflects market expectations for the success of its strategy to commercialize promising Western drugs. It demonstrates investor confidence in the growth of the Chinese pharmaceutical market and the company's ability to select successful drug candidates.
%20P%2FE%20Zai%20Lab%20Limited&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Zai-Lab-Limited&v=1772513441325 "Chart of the company's future (projected) P/E Zai Lab Limited")
Future (projected) P/E of the market segment - Pharma holding
Zai Lab is a biopharmaceutical company focused on licensing, developing, and commercializing innovative drugs in China and globally. This chart shows its expected future profitability, allowing for comparison with other companies and assessing the success of its unique business model, which bridges the gap between East and West.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20holding&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-holding&v=1772513441332 "Future (projected) P/E graph of the market segment - Pharma holding")
Future (projected) P/E of the market as a whole
Zai Lab Limited is a Chinese biopharmaceutical company that licenses and develops innovative drugs for the Chinese market. Its success depends on regulatory approval and commercial launches. Global market sentiment, as reflected here, is less important than the specifics of China's healthcare system and regulation.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772513441345 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Zai Lab Limited
Zai Lab Limited is a biopharmaceutical company focused on licensing and developing Western drugs for the Chinese market. Its business model is based on the accelerated launch of proven drugs into a vast and rapidly growing market. This chart shows how successfully the company is commercializing its portfolio and transitioning from losses to sustainable profitability.
Profit of companies in the market segment - Pharma holding
Zai Lab is a Chinese biopharmaceutical company that licenses and develops innovative drugs for the Chinese and global markets. Its business model is based on partnerships with Western biotech companies. This chart reflects the explosive growth of China's pharmaceutical market, where companies like Zai Lab act as a bridge for global innovation.
Overall market profit
Zai Lab is a Chinese biopharmaceutical company that licenses and develops Western drugs for the Chinese market. Its success depends on regulatory approval and the growth of the Chinese healthcare market. This chart, applied to China, reflects rising affluence, which is driving demand for modern medicines.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Zai Lab Limited
Zai Lab is a Chinese biopharmaceutical company that licenses and develops innovative drugs for the Chinese and global markets. Its business model is to serve as a bridge between Western developments and the East. This chart shows the analyst consensus forecast, which is a bet on the growth of the Chinese pharmaceutical market and the success of the company's drug portfolio.
%20profit%20of%20the%20company%20Zai%20Lab%20Limited&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Zai-Lab-Limited&v=1772513441440 "Graph of future (projected) profit of the company Zai Lab Limited")
Future (predicted) profit of companies in the market segment - Pharma holding
Zai Lab is a Chinese biopharmaceutical company focused on licensing and developing innovative drugs for the Chinese market. The company's business model allows it to quickly bring Western-proven drugs to market. This chart shows profitability projections for the pharmaceutical sector, helping to assess the success of Zai Lab's strategy in one of the world's largest markets.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20holding&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-holding&v=1772513441467 "Graph of future (predicted) profits of companies in a market segment - Pharma holding")
Future (predicted) profit of the market as a whole
Zai Lab is a Chinese biopharmaceutical company that licenses and develops drugs for the Chinese market. Its success depends on the selection of promising drugs, regulatory approvals, and commercial launches. For Zai Lab, the state of China's healthcare system and scientific trends are far more important than global corporate profit forecasts.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772513441480 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Zai Lab Limited
Zai Lab is a biopharmaceutical company focused on bringing innovative medicines to the Chinese market. This chart shows how the market values its revenue and licensed drug portfolio. This valuation reflects the enormous potential of the Chinese healthcare market and its strategic partnerships.
P/S market segment - Pharma holding
Zai Lab Limited is a biopharmaceutical company focused on developing and commercializing innovative drugs for the treatment of oncology and autoimmune diseases in China and globally. This chart reflects the average revenue estimate in the biotech sector. It provides an insight into how investors perceive Zai Lab's strategy for licensing promising drugs.
P/S of the market as a whole
Zai Lab is a Chinese biopharmaceutical company that licenses, develops, and commercializes innovative drugs from Western companies in the Chinese market. Their business model bridges global innovation and a vast market. This chart helps understand how investors assess the potential and risks of China's pharmaceutical sector through the lens of ZLAB.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Zai Lab Limited
Zai Lab is a biopharmaceutical company focused on licensing and developing innovative drugs for the Chinese market. This chart reflects how the market values its future revenue. This estimate is based on the sales potential of its existing pipeline and the success of bringing new drugs from its extensive pipeline to market.
%20P%2FS%20Zai%20Lab%20Limited&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Zai-Lab-Limited&v=1772513441544 "The graph of the company's future (projected) P/S Zai Lab Limited")
Future (projected) P/S of the market segment - Pharma holding
Zai Lab is a biopharmaceutical company that licenses promising drugs from Western companies for development and commercialization in China and globally. This unique cross-border business model is a key driver of innovation. This chart compares how investors view its strategy and pipeline compared to other biotech firms.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20holding&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-holding&v=1772513441551 "Future (projected) P/S market segment graph - Pharma holding")
Future (projected) P/S of the market as a whole
Zai Lab is a biopharmaceutical company focused on licensing and developing innovative drugs for the Chinese market. This chart, reflecting global sentiment, influences Western companies' willingness to collaborate and investors' appetite. Market optimism is facilitating new partnerships and raising the capital Zai Lab needs to conduct clinical trials.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772513441574 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Zai Lab Limited
Zai Lab is a biopharmaceutical company focused on licensing, developing, and commercializing innovative drugs in China. This chart shows the revenue from sales of drugs for which it acquired rights from Western partners. The growth here reflects the growing demand for advanced medicines in China's vast pharmaceutical market.
Sales of companies in the market segment - Pharma holding
Zai Lab Limited is a biopharmaceutical company focused on licensing, developing, and commercializing innovative medicines for the Chinese and global markets. Its business can be segmented by specific drugs or therapeutic areas. This chart shows the revenue from one of its key products, reflecting its success in the strategically important Chinese market.
Overall market sales
Zai Lab Limited is a biopharmaceutical company focused on bringing innovative Western-developed drugs to the Chinese market. Its business model leverages the growing demand for advanced treatments in China. Zai Lab's success reflects not only the globalization of the pharmaceutical market but also rising prosperity and healthcare spending in emerging economies.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Zai Lab Limited
Zai Lab is a Chinese biopharmaceutical company that licenses and develops innovative drugs from Western partners for the Chinese and international markets. Its revenue forecast is dependent on the successful commercialization of these drugs, reflecting the growing demand for modern medicines in China and the company's ability to effectively bring them to market.
%20sales%20of%20the%20company%20Zai%20Lab%20Limited&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Zai-Lab-Limited&v=1772513441680 "Schedule of future (projected) sales of the company Zai Lab Limited")
Future (projected) sales of companies in the market segment - Pharma holding
Zai Lab Limited is a biopharmaceutical company focused on licensing and developing Western drugs for the Chinese market. This chart shows revenue expectations for China's pharmaceutical sector. It reflects analysts' views on the growing demand for innovative drugs and the country's regulatory environment, which is key to Zai Lab's business model.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20holding&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-holding&v=1772513441710 "Schedule of future (projected) sales of companies in the market segment - Pharma holding")
Future (projected) sales of the market as a whole
Zai Lab, a biopharmaceutical company focused on bringing Western drugs to the Chinese market, depends on the growth of the Chinese healthcare market. This chart of overall sales forecasts, reflecting global trends, indirectly indicates economic health, allowing countries to increase spending on modern medicine.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772513441727 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Zai Lab Limited
Zai Lab Limited is a biopharmaceutical company focused on licensing, developing, and commercializing innovative drugs in China. Its business model bridges the gap between Western innovation and the Chinese market. This chart shows how revenue from existing drugs compares to clinical trial costs for new candidates.
Market segment marginality - Pharma holding
Zai Lab is a Chinese biopharmaceutical company that licenses and develops innovative drugs for the Chinese market. Their "in-license/develop" business model allows them to quickly bring promising drugs developed in the West to market. This chart demonstrates the effectiveness of this strategy for "bridging" global innovation with China's vast market.
Market marginality as a whole
Zai Lab Limited is a biopharmaceutical company focused on bringing innovative medicines to the Chinese and global markets. Its business model is based on partnerships with global pharmaceutical companies. This chart reflects overall profitability, but for ZLAB, the vast and growing healthcare market in China offers unique opportunities for growth and profitability.
Employees in the company, segment and market as a whole
Number of employees in the company Zai Lab Limited
Zai Lab is a Chinese biopharmaceutical company that licenses and develops innovative drugs for the Chinese market. This chart shows the rapid growth of its scientific and commercial teams. This growth reflects a successful business model for accelerating the introduction of Western drugs to the vast Chinese market.
Share of the company's employees Zai Lab Limited within the market segment - Pharma holding
Zai Lab Limited is a biopharmaceutical company focused on bringing innovative drugs to the Chinese market. Its model requires a large team to conduct clinical trials and commercialization. This chart illustrates its growing importance as an employer in China's dynamic pharmaceutical sector.
Number of employees in the market segment - Pharma holding
Zai Lab is a biopharmaceutical company focused on licensing, developing, and commercializing innovative drugs in China. This chart reflects employment within pharmaceutical holding companies. The growing number of specialists in this field demonstrates the rapid development of the Chinese healthcare market and its integration into the global pharmaceutical industry.
Number of employees in the market as a whole
Zai Lab Limited is a biotechnology company focused on the Chinese market. While its business depends on research success, the overall economic situation is important. A strong labor market and economic growth support increased healthcare spending, which facilitates the faster adoption and commercialization of new drugs.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Zai Lab Limited (ZLAB)
Zai Lab is a Chinese biopharmaceutical company that licenses and develops innovative drugs for the Chinese market. The high market capitalization per employee, visible in this chart, reflects the value of its pipeline of drug candidates and its expertise in conducting clinical trials in China, a key intellectual asset.
%20of%20the%20company%20Zai%20Lab%20Limited%20(ZLAB)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Zai-Lab-Limited-ZLAB&v=1772513441956 "Chart of market capitalization per employee (in thousands of dollars) of the company Zai Lab Limited (ZLAB)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma holding
Zai Lab (ZLAB) is a Chinese biopharmaceutical company that uses an "in-licensing" model: it purchases the rights to Western drugs for sale in China. It's an "R&D-light" but "commercial-heavy" model. This chart shows the market value per employee in this "intermediary" pharma model.
%20by%20market%20segment%20-%20Pharma%20holding&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-holding&v=1772513441968 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma holding")
Market capitalization per employee (in thousands of dollars) for the overall market
Zai Lab Limited is a Chinese biopharmaceutical company that licenses and develops innovative drugs for the Chinese market. Their model is to identify promising drugs in the West and adapt them. The chart shows how the market evaluates the team's ability to select and promote successful therapeutics.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772513442005 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Zai Lab Limited (ZLAB)
Zai Lab Limited is a biopharmaceutical company based in China and the US, focusing on licensing and developing Western drugs for the Chinese market (and vice versa). This chart demonstrates the effectiveness of their R&D and business model. It measures how successfully their team of scientists and business development managers can select, develop, and commercialize promising drugs.
%20Chart%20Zai%20Lab%20Limited%20(ZLAB)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Zai-Lab-Limited-ZLAB&v=1772513442030 "Company Profit Per Employee (in thousands of dollars) Chart Zai Lab Limited (ZLAB)")
Profit per employee (in thousands of dollars) in the market segment - Pharma holding
Zai Lab (ZLAB) is a "Chinese" biotech company. Their model is "in-license": they "license" Western drugs (R&D) for sale in China. This chart shows the benchmark for "Pharma Holding" (Licensing). The benchmark here is volatile. Earnings per employee depend on the success of R&D partners and the speed of drug approvals in China.
%20in%20the%20market%20segment%20-%20Pharma%20holding&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-holding&v=1772513442058 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma holding")
Profit per employee (in thousands of dollars) for the market as a whole
Zai Lab (ZLAB) is a Shanghai-based biopharmaceutical company. Their business model is to license promising Western drugs (in development) for rapid market launch in China. This graph, showing average profit per employee, is important for biotech. It allows one to assess how profitable a sector with significant clinical research and marketing is relative to its workforce.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772513442106 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Zai Lab Limited (ZLAB)
Zai Lab is a Chinese biopharmaceutical company that licenses and develops innovative drugs for the Chinese market. This chart reflects the success of its business model. The growth in revenue per employee demonstrates how effectively the company is bringing Western drugs to market, meeting the huge demand for modern medicine in China.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Zai-Lab-Limited-ZLAB&v=1772513442123 "Sales chart per company employee Zai Lab Limited (ZLAB)")
Sales per employee in the market segment - Pharma holding
Zai Lab is a biopharmaceutical company focused on China. Their model is to license promising Western drugs (in development) for the Chinese market. This chart shows revenue per employee. Comparison with the industry helps assess the success of their "bridge" business model and how effectively they market their drugs in China.
Sales per employee for the market as a whole
Zai Lab is a Chinese biopharmaceutical company operating under the "in-license" model. Rather than conducting early-stage research, they acquire or license promising Western drugs (already in Phase II or III) for rapid registration and sale in China. This chart shows how effectively their business development and sales team commercializes this portfolio of licensed drugs.
Short shares by company, segment and market as a whole
Shares shorted by company Zai Lab Limited (ZLAB)
Zai Lab is a Chinese biopharmaceutical company. Their strategy is to license promising Western drugs (in development) for promotion and sale in the Chinese market. Their business model depends on successful deals and approvals from Chinese regulators. This chart shows the number of skeptics who fear the risks of doing business in China or the potential for failure in their drug portfolio.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Zai-Lab-Limited-ZLAB&v=1772513442173 "Short Shares Chart for the Company Zai Lab Limited (ZLAB)")
Shares shorted by market segment - Pharma holding
Zai Lab (ZLAB) is a Chinese biopharmaceutical company that licenses and develops innovative drugs (often Western) for the Chinese and global markets, focusing on oncology. This chart shows the odds against the Chinese biotech sector. It reflects concerns about regulatory pressure, geopolitics, and the high level of competition in the Chinese pharmaceutical market.
Shares shorted by the overall market
Zai Lab (ZLAB) is a Chinese biotech company. This Short_All chart highlights global market pessimism. When it rises, it hits ZLAB twice: investors flee emerging markets (China risk) and simultaneously dump speculative stocks (biotech).
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Zai Lab Limited (ZLAB)
Zai Lab is a Chinese biotech company that licenses and develops drugs for China. The business carries dual risks (biotech and China). A ZLAB score above 70 may reflect R&D success or optimism about China. A score below 30 is associated with setbacks, regulatory pressure, or a recession in China.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Zai-Lab-Limited-ZLAB&v=1772513442270 "RSI 14 indicator chart for the company's stock Zai Lab Limited (ZLAB)")
RSI 14 Market Segment - Pharma holding
Zai Lab (ZLAB) is a Shanghai-based biotech company that licenses and launches Western innovative drugs in the Chinese market. The RSI_14_Seg for their biotech segment reflects the overall sentiment. It helps us understand whether ZLAB's performance reflects their licensing success or whether the entire sector is oversold amid regulatory risks in China.
RSI 14 for the overall market
Zai Lab (ZLAB), a Chinese biotech company, sees this chart as a reflection not only of risk appetite but also of geopolitical "temperature." During periods of euphoria, investors are willing to invest in Chinese biotech. During moments of panic, exacerbated by tensions between the US and China, capital flees Chinese stocks, regardless of Zai Lab's R&D success.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast ZLAB (Zai Lab Limited)
Zai Lab is a Chinese biopharmaceutical company operating under the in-license model. It acquires the rights to promising Western drugs (often for cancer treatment) for development and commercialization in China. This chart shows the average analyst forecast. Their target prices depend on the sales success of existing drugs and the company's ability to secure new profitable deals.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-ZLAB-Zai-Lab-Limited&v=1772513442354 "A chart showing analyst consensus forecasts for the expected stock price. ZLAB (Zai Lab Limited)")
The difference between the consensus estimate and the actual stock price ZLAB (Zai Lab Limited)
Zai Lab (ZLAB) is a leading Chinese biotech company that serves as a bridge for Western innovation by licensing and bringing cutting-edge drugs to the Chinese market. This chart shows their business model assessment. It measures the gap between the price and the consensus target, reflecting the potential analysts see in their licensed drug portfolio.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-ZLAB-Zai-Lab-Limited&v=1772513442360 "A chart showing the difference between the consensus forecast and the actual stock price. ZLAB (Zai Lab Limited)")
Analyst consensus forecast for stock prices by market segment - Pharma holding
Zai Lab is a Chinese biopharmaceutical company. Its model is a "bridge" between the West and the East: it licenses promising Western drugs for development and sale in China. This chart shows analysts' general expectations for the pharmaceutical holding sector. It reflects whether experts believe the Chinese pharmaceutical market will grow.
Analysts' consensus forecast for the overall market share price
Zai Lab is a biotech company operating under the licensing model and developing innovative drugs (oncology, autoimmune) for the Chinese market. This chart shows the overall sentiment in global markets. For Zai Lab, whose valuation depends on risk appetite, general optimism is important, but investors also weigh it against China-specific regulatory and geopolitical risks.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Zai Lab Limited
Zai Lab is a Chinese biotech company with a unique in-licensing model. They identify promising Western drugs (such as Novocure) and obtain the rights to develop and market them in China. This chart evaluates their bridging strategy, measuring their ability to successfully conduct clinical trials and commercialize a portfolio of licensed drugs in the vast Chinese market.
AKIMA Market Segment Index - Pharma holding
Zai Lab is a Chinese biotech innovator; the company operates using a hybrid model: it licenses breakthrough Western drugs (for cancer) for the Chinese market and develops its own drugs. This summary metric evaluates R&D. The graph shows the average value for the segment. This is a benchmark: how does Zai Lab's hybrid (China + R&D) model differentiate it from the average pharmaceutical company?
The AKIM Index for the overall market
Zai Lab is a bridge for biotech. The company doesn't invent (R&D), but licenses advanced Western drugs (cancer and autoimmune) for sale in the Chinese market. This chart, showing the average (global/US) market performance, serves as a benchmark. It helps assess how ZLAB, which is dependent on Chinese regulators, compares to overall macroeconomic trends.
